AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca is conducting a Phase I study titled A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004. The study aims to evaluate how different levels of liver impairment affect the pharmacokinetics, safety, and tolerability of AZD5004, a drug administered in a single oral dose.
The intervention being tested is AZD5004, a drug designed to be taken orally under fasted conditions. It is being tested across four groups, including those with mild, moderate, and severe hepatic impairment, as well as a control group with normal liver function.
The study is interventional, non-randomized, and open-label, with a parallel group design. Participants are divided into four groups based on their liver function, and all receive the same treatment to assess the drug’s effects.
The study began on December 19, 2024, and the latest update was submitted on June 30, 2025. These dates are crucial as they mark the study’s progress and provide a timeline for when results might be expected.
This study’s progress could impact AstraZeneca’s stock performance, as positive results may boost investor confidence and market value. In the competitive pharmaceutical industry, advancements in drug efficacy and safety can significantly influence market dynamics.
The study is currently ongoing, with further details available on the ClinicalTrials portal.